公开(公告)号：US11926858B2

公开(公告)日：2024-03-12

申请号：US17657787

申请日：2022-04-04

Applicant: GLYCOM A/S

Inventor： Margit Pedersen ,  Manos Papadakis ,  Peter Becker ,  Eric Samain ,  Pauline Peltier-Pain ,  Katrine Bych ,  Ted Johanson ,  Elise Champion ,  Gyula Dekany

IPC: C12P19/18 ,  C07K14/245 ,  C12N9/10 ,  C12N9/12 ,  C12N9/24 ,  C12N9/38 ,  C12N15/52 ,  C12P19/12

CPC classification number: C12P19/18 ,  C07K14/245 ,  C12N9/1029 ,  C12N9/1051 ,  C12N9/1205 ,  C12N9/2402 ,  C12N9/2471 ,  C12N15/52 ,  C12P19/12 ,  C12Y203/01018 ,  C12Y204/01149 ,  C12Y302/01023 ,  C12Y302/01026 ,  C12Y204/01094

Abstract: The invention relates to a genetically modified microorganism for making a oligosaccharide, preferably of 3-8 monosaccharide units, more preferably of 3-5 monosaccharide units, particularly a HMO, which comprises one or more genes encoding a sucrose utilization system, so the microorganism can use sucrose as a carbon and energy source.

公开(公告)号：US11896604B2

公开(公告)日：2024-02-13

申请号：US17353730

申请日：2021-06-21

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7016 ,  A61P1/12

CPC classification number: A61K31/702 ,  A61K31/7016 ,  A61P1/12 ,  A61K2300/00

Abstract: The application relates to a method for the prophylaxis or treatment of non-infectious diarrhea in a human, the method comprising administering to the human an effective amount of one or more human milk oligosaccharides.

公开(公告)号：US11833165B2

公开(公告)日：2023-12-05

申请号：US17341039

申请日：2021-06-07

Applicant: Glycom A/S

Inventor： Thierry Hennet ,  Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7004 ,  A61K31/7012 ,  A61P1/04 ,  A23L33/21 ,  A23C9/20

CPC classification number: A61K31/702 ,  A23C9/206 ,  A23L33/21 ,  A61K31/7004 ,  A61K31/7012 ,  A61P1/04 ,  A23V2002/00 ,  A61K31/7004 ,  A61K2300/00 ,  A61K31/7012 ,  A61K2300/00 ,  A61K31/702 ,  A61K2300/00

Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient one or more neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof.

公开(公告)号：US11684630B2

公开(公告)日：2023-06-27

申请号：US17099306

申请日：2020-11-16

Applicant: GLYCOM A/S

Inventor： Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61P25/22 ,  A61P25/24 ,  A61P1/00 ,  C07H3/06 ,  A23L33/15

CPC classification number: A61K31/702 ,  A23L33/15 ,  A61P1/00 ,  A61P25/22 ,  A61P25/24 ,  C07H3/06 ,  A61K31/702 ,  A61K2300/00

Abstract: A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

公开(公告)号：US20230133446A1

公开(公告)日：2023-05-04

申请号：US17906701

申请日：2021-01-29

Applicant: GLYCOM A/S

Inventor： Pierre CHASSAGNE

IPC: A23C9/20 ,  C07H3/06 ,  C12P19/18 ,  F26B5/12 ,  F26B15/18 ,  A23C1/03 ,  A23L33/125 ,  A23L3/48 ,  A23P10/22 ,  A23L33/00 ,  A23C9/146 ,  A23C9/142

Abstract: Various methods are provided for providing a solid HMO product, said methods including drum-drying, belt drying, preferably vacuum bed drying, or granulation. Solid HMO products are obtained via said methods, as well as solid HMO products per se. The methods can provide solid HMO products which are different to those achieved via other methods.

公开(公告)号：US20230114668A1

公开(公告)日：2023-04-13

申请号：US17906131

申请日：2021-03-12

Applicant: Glycom A/S

Inventor： Getachew S. MOLLA ,  Pierre CHASSAGNE

IPC: C07H3/06 ,  C07H1/06 ,  C13B30/02

Abstract: The invention relates to a method for selective crystallization of 2′-FL from an aqueous solution comprising 2′-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution.

公开(公告)号：US20230000886A1

公开(公告)日：2023-01-05

申请号：US17780869

申请日：2020-11-27

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Dorthe Seitzberg ,  Ingvild Dybdrodt Amundsen

IPC: A61K31/702 ,  A61P1/12

Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in a lac-tose-intolerant, IBS patient; reintroducing a source of lactose into the diet of a lactose-intolerant, IBS patient while prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in the IBS patient; and/or reducing the severity and/or occurrence of non-gastrointestinal symptoms in a lactose-intolerant, IBS patient.

公开(公告)号：US11529365B2

公开(公告)日：2022-12-20

申请号：US17114850

申请日：2020-12-08

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K45/06 ,  A61P31/00 ,  A61P3/10 ,  A61P29/00 ,  A61K35/20 ,  A61K35/00

Abstract: A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.

公开(公告)号：US11529364B2

公开(公告)日：2022-12-20

申请号：US17093337

申请日：2020-11-09

Applicant: GLYCOM A/S

Inventor： Emma Elison ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7012 ,  A61K31/7004 ,  A61K9/00

Abstract: A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.

公开(公告)号：US11491171B2

公开(公告)日：2022-11-08

申请号：US17026616

申请日：2020-09-21

Applicant: GLYCOM A/S

Inventor： Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A23L33/00 ,  A23L33/15 ,  A61P25/22 ,  A61P25/24

Abstract: A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.